Country for PR: United States
Contributor: PR Newswire New York
Wednesday, May 15 2019 - 05:09
Sekisui Diagnostics Invests $1.9 million in Microbial Biopharma CDMO Business
LEXINGTON, Massachusetts, May 15, 2019 /PRNewswire-AsiaNet/ --

Sekisui Diagnostics Enzyme business announces the completion of a new 
BioProcess Innovation Centre at the site in Maidstone, Kent by the end of 2019, 
following a $1.9 million investment. This investment is part of a long-term 
investment strategy to grow its share of the Microbial Biopharma CDMO market, 
with future investment expected to focus on expanding cGMP manufacturing 

Photo - 
Logo - 

Previously part of Genzyme Diagnostics, Sekisui Diagnostics' Enzyme business 
launched its Microbial Biopharma CDMO service offering, BioProduction by 
Sekisui ( 
), in 2017, building on over 40 years' experience in this field. The new 
BioProcess Innovation Centre will more than double its development laboratory 
space to facilitate Process Transfer and Development. Specialized in expression 
and purification from microbial fermentation, the group has wide experience, 
including but not limited to recombinant systems such as E. coli and Pichia 
pastoris, with associated purification and analytical technologies. Its main 
expertise lies in the production of enzymes, however its capabilities are also 
suitable for plasmids, antibody fragments, and other protein production. With 
production capabilities from 20L to 5,000L, Sekisui handles projects from 
pre-clinical through to commercialization.

"Over many years we have built both a technical and operational competency and 
expertise in enzyme production and microbial fermentation," said Robert 
Schruender, President & CEO of Sekisui Diagnostics and Sekisui Medical Board 
Member. "As the Biopharma CDMO market grows, we aim to further leverage this 
capability to grow our share in this market. This investment represents our 
commitment to serve our customers with innovative process development 

About Sekisui Diagnostics: 
Sekisui Diagnostics is a global company committed to improving patient's lives 
by providing innovative medical diagnostics to physicians and laboratories 
through a global commercial network.  Product lines include clinical chemistry 
and coagulation systems, reagents, rapid test kits, point-of-care systems. The 
Enzyme business forms part of this group and, in addition to BioProduction by 
Sekisui ( 
), offers a broad portfolio of Diagnostic enzymes and critical raw materials ( 

SOURCE  Sekisui Diagnostics

CONTACT: Lisa Turner, Marketing Communications Director, +1 (858) 777-2660,